May 29 |
Biohaven stock falls 30% premarket amid drug updates
|
May 29 |
Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
|
May 29 |
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
|
May 22 |
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
|
May 18 |
Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge
|
May 15 |
Director Gregory Bailey Acquires 15,000 Shares of Biohaven Ltd (BHVN)
|
May 14 |
Down -24.55% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
|
May 13 |
Down -32.76% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
|
May 9 |
Biohaven reports Q1 results
|
May 9 |
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
|